- At the risk of inducing eteplirsen/ drisapersen news-fatigue, it's worth noting that shares of Sarepta Therapeutics (SRPT +17.2%) have reversed course dramatically over the course of the day.
- Investors and the sell-side alike have apparently digested Friday's drisapersen (RNA -67.1%) news and determined that the chances of a favorable regulatory outcome for eteplirsen are still good.
- Also, Piper Jaffray joins Stifel and Deutsche (see previous) in the bull camp, upgrading SRPT to Overweight (price target is $58).
- More here
Sarepta makes sharp move to the upside as the Street gets bullish
Sep 20 2013, 13:04 ET